On January 17, ASE joined a coalition of cardiovascular groups in a comment letter to CMS applauding their proposed decision to enlist Medicare coverage of transcatheter tricuspid value replacements (TTVR) under coverage with evidence development (CED). The comments acknowledge the novel approach CMS is taking that requires the trial sponsor to lead the delivery of a breakthrough device. The societies offer recommendations on best practices to carry out CMS’ goals outlined in the proposed decision.
Publishing date
January 17, 2025
Related Resources
Advanced Imaging
ASE Joins Letter Responding to Appropriate Use Criteria Provisions in Patients First Act and the ROOT Act
On September 14, ASE joined the American College...
Advocacy
ASE Submits Comments on the CY 2027 Medicare Physician Fee Schedule Proposed Rule
On September 14, ASE submitted comments to CMS...
Advocacy
ASE Joins Comments on the CY 2027 Medicare Physician Fee Schedule Proposed Rule
On September 1, ASE joined the Alliance of...